# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Rodman & Renshaw initiates coverage on Passage Bio (NASDAQ:PASG) with a Buy rating and announces Price Target of $7.
Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neu...
Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $14 t...
Canaccord Genuity analyst Whitney Ijem reiterates Passage Bio (NASDAQ:PASG) with a Buy and maintains $14 price target.
Appointed Kathleen Borthwick as Chief Financial Officer, effective March 1, 2024: Ms. Borthwick previously served as the comp...